Updated: Dec 16, 2021
A team of medical and pharmaceutical experts has founded SynaptixBio, an Oxford-based research company working to develop the world’s first disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting condition. This is a sponsored research agreement with Children’s Hospital of Philadelphia (CHOP) in the US.
To continue reading please go to the article on Drug Discovery World
Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr
SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst
A new biotech business SynaptixBio has been launched to tackle one of the world’s rarest neurodegenerative diseases. SynaptixBio is working to develop the world’s first disease-modifying treatment for
